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Abstract
We describe a female proband with primordial dwarfism, skeletal dysplasia, facial
dysmorphism, extreme dyslipidaemic insulin resistance and fatty liver associated with a
novel homozygous frameshift mutation in POC1A, predicted to affect two of the three
protein products of the gene. POC1A encodes a protein associated with centrioles
throughout the cell cycle and implicated in both mitotic spindle and primary ciliary function.
Three homozygous mutations affecting all isoforms of POC1A have recently been
implicated in a similar syndrome of primordial dwarfism, although no detailed metabolic
phenotypes were described. Primary cells from the proband we describe exhibited
increased centrosome amplification and multipolar spindle formation during mitosis,
but showed normal DNA content, arguing against mitotic skipping, cleavage failure or
cell fusion. Despite evidence of increased DNA damage in cells with supernumerary
centrosomes, no aneuploidy was detected. Extensive centrosome clustering both at
mitotic spindles and in primary cilia mitigated the consequences of centrosome
amplification, and primary ciliary formation was normal. Although further metabolic studies
of patients with POC1A mutations are warranted, we suggest that POC1A may be added to
ALMS1 and PCNT as examples of centrosomal or pericentriolar proteins whose dysfunction
leads to extreme dyslipidaemic insulin resistance. Further investigation of links between
these molecular defects and adipose tissue dysfunction is likely to yield insights into
mechanisms of adipose tissue maintenance and regeneration that are critical to
metabolic health.
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Introduction
Insulin action and linear growth are intimately linked,
with crosstalk between insulin action and growth hormo-
ne/IGF1 signalling at multiple levels in liver and other
tissues. This is attested to by the insulin resistance reported
in the context of mutations in either the IGF1 receptor
(Gannage-Yared et al. 2013) or the IGF acid labile subunit
in humans (Hogler et al. 2014) and, conversely, by the
marked linear growth impairment caused by biallelic INSR
mutations (Semple et al. 2010, 2011). However growth and
insulin action have links beyond these well-established
endocrine mechanisms. Indeed, a subset of forms of
primordial dwarfism caused by cellular defects with no
obvious link to insulin action also feature severe dyslipi-
daemic insulin resistance. These include osteodysplastic
primordial dwarfism of Majewski type 2 (MOPDII)
(Huang-Doran et al. 2011), caused by recessive mutations
in the pericentrosomal protein PCNT (Rauch et al. 2008), a
recently described form of dwarfism caused by defects in
the SUMO ligase NSMCE2 (Payne et al. 2014a), which is
involved in accurate DNA repair in replicating cells, and
Bloom syndrome (Diaz et al. 2006), caused bymutations in
the BLM DNA helicase (Ellis et al. 1995).
Most known forms of primordial dwarfism, however,
have not been reported to be associated with insulin
resistance. Moreover, other pleiotropic disorders have
been described affecting either another large component
of the centrosome, ALMS1, or another DNA helicase,
WRN. Interestingly both of the resulting clinical
syndromes, namely Alstro¨m syndrome and Werner
syndrome, also feature severe insulin resistance and
dyslipidaemia (Marshall et al. 2011, Watanabe et al.
2013). Increasing understanding of the mechanistic links
among insulin action, growth, and cell autonomous
defects in centrosomal function and DNA damage repair
is likely to yield novel insights into the pathogenesis of
systemic insulin resistance, which a substantial body of
evidence has implicated as an important mediator of the
link between obesity and pathologies such as type 2
diabetes, fatty liver disease, polycystic ovary syndrome
and some cancers (Savage & Semple 2010, Parker et al.
2011, Semple et al. 2011, Stears et al. 2012).
A new form of primordial dwarfism caused by a
homozygous genetic defect in the luminal centriolar
protein POC1A was recently described (Sarig et al. 2012,
Shaheen et al. 2012, Koparir et al. 2015), and we now add
to this by reporting a further affected patient with a
frameshift mutation predicted to affect two out of three
POC1A isoforms. This was associated with supernumerary
centrosomes and multipolar mitotic spindles in primary
cells, and with sustained and extreme dyslipidaemic
insulin resistance. This adds a further piece to the puzzle
regarding the pathogenic mechanisms linking centro-
some/ciliary dysfunction and metabolic disease.
Materials and methods
Patients and clinical studies
All human studies were approved by the United Kingdom
National Health Service Research Ethics Committee. The
proband and family provided written informed consent,
and studies were conducted in accordance with the
principles of the Declaration of Helsinki. For biochemical
assays, venous blood was drawn in the fasting state and
plasma immediately extracted then stored at K20 8C.
Insulin, leptin and adiponectin were assayed using two-
step, time-resolved AutoDELFIA immunoassays described
previously (Semple et al. 2006). Other analytes were
determined in accredited clinical diagnostic laboratories
of the referring hospital. For oral glucose tolerance testing,
1.75 g glucose/kg was administered after a 10 h fast and
blood samples taken at the times indicated for determi-
nation of plasma glucose and insulin.
Body composition was measured by Lunar Prodigy
dual-energy X-ray absorptiometry (GE Lunar). Abdominal
fat distribution, including hepatic triglyceride content,
was assessed by proton magnetic resonance spectroscopy
(MRS), using a Siemens 3T Tim Trio MR scanner (Siemens
Healthcare, Erlangen, Germany). All protocols have been
described in detail previously (Semple et al. 2009).
Genetic studies
Whole exome sequencing and variant calling of genomic
DNA extracted from peripheral blood leukocytes was
performed as part of the UK10K Project as described
previously (Futema et al. 2012). Calls were annotated with
1000 Genomes Phase 1 integrated callset v3 allele
frequencies (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/
phase1/analysis_results/integrated_call_sets) and the
NCBI dbSNP database build 137 (ftp://ftp.ncbi.nih.gov/
snp/organisms/human_9606/database/b137_archive/
organism_data/). Functional annotation was added using
Ensembl Variant Effect Predictor v2.8 (McLaren et al. 2010)
against Ensembl build 70. Variants were further annotated
with allele frequencies from the Exome Variant Server,
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NHLBI GO Exome Sequencing Project (ESP), Seattle, WA
(URL: http://evs.gs.washington.edu/EVS/) (April 2013),
the UK10K Cohorts (REL-2012-06-02) and Exome (REL-
2013-04-20) groups (www.UK10K.org) and exome-wide
sequencing data from 409 control individuals from the
CoLaus Cohort (Firmann et al. 2008). Raw exome sequence
data is available from the European Genome-Phenome
Archive (https://www.ebi.ac.uk/ega/home; accession
numbers EGAN00001083652 and EGAN00001028741).
Variants were defined as potentially functional if they
were non-synonymous, resulted in loss or gain of a stop
codon or a frameshift, or occurred within essential splice
sites. Those unlikely to have a functional impact were
removed, as were all heterozygous variants and those
found with a non-reference allele frequency O1% in
individuals of European descent from any of the anno-
tated control populations (1000 genomes, UK10K cohorts
and exomes, NHLBI exomes and CoLaus exomes).
Variants present in the unaffected sister or failing to pass
the quality filters were also removed. The remaining
variants were then evaluated as described previously
(Payne et al. 2014b). Comments on predicted alternative
protein products of the POC1A gene are based on Ensembl
build 70.
Cell culture
Dermal fibroblasts derived from skin biopsy of proband
and healthy controls were grown in DMEM (D6546,
Sigma) supplemented with 10% FCS (HyClone), 4 mM
L-glutamine (G7513, Sigma), 1% penicillin-streptomycin
(P0781, Sigma) in a humidified incubator (37 8C, 5% CO2).
Primary cilia formation was induced by culturing cells
in serum-free medium for 24 h.
cDNA synthesis and sequencing
Total RNA was prepared using RNeasy Mini Kits (Qiagen)
with a DNase digestion step to eliminate contaminating
DNA, and was quantified on a NanoDrop ND-1000
(Thermo Scientific, Waltham, MA, USA). First strand
cDNA was reverse-transcribed from 400 ng of total RNA
using an ImProm-II Reverse Transcription System (Pro-
mega) with random hexamer as the primer, according to
the manufacturer’s protocol. PCR was carried out with a
GoTaq Green Master Mix (Promega) and gene-specific
primers. Primers were custom-designed and synthesized
by Sigma: POC1A forward primer (5 0–3 0) GAACAAGT-
GATGGTTTGGAAGA, POC1A reverse primer (5 0–3 0)
CCCAAGTCCCATGGTACAAA. PCR products were
examined by 1% agarose gel followed by Exo1/SAP
treatment. Sequencing reactions were performed with a
POC1A forward primer (5 0–3 0) CAGAAGTGGACTTCCC-
TGTC and the preceding reverse primer.
Western blotting
Cells were washed with ice-cold PBS and harvested in
M-PER Mammalian Protein Extraction reagent (Thermo
Scientific) containing protease inhibitor mini complete
cocktail (Roche) at a 1:7 ratio. Proteins weremixed with an
equal volume of Laemmli sample buffer (#161-0737, Bio-
Rad), denatured at 95 8C and resolved by SDS–PAGE before
transfer to polyvinylidene-fluoride membranes using
the iBlot system (Invitrogen). Blots were blocked with 5%
BSA in TBST (50 mMTris–HCl, pH7.6, 150 mMNaCl, 0.1%
Tween-20) and probed overnight at 4 8C with anti-POC1A
(HPA040600, Sigma) or anti-calnexin (ab75801, Abcam,
Cambridge, UK) antibody. Bound primary antibody was
detected by HRP conjugated secondary antibodies,
followed by Immobilon Western chemiluminescent HRP
substrate (WBKLS0500, Millipore, Watford, UK).
Immunofluorescence analysis
Cells on coverslips were fixed in 4% paraformaldehyde in
PBS for 10 min followed by one wash with PBS, permea-
bilization in 0.2% Triton X-100 in PBS for 5 min, and three
washes with PBS (5 min each wash). Coverslips were
blocked with blocking buffer (10% horse serum, 1% BSA,
0.02% NaN3, 1! PBS) for 1 h, washed with PBS and
incubated with anti-ALMS1 (ab84892, Abcam) and anti-
acetylated tubulin (T7451, Sigma–Aldrich) in 1% BSA in
PBS overnight at 4 8C. After washing with PBS, the cells
were incubated with 1:1000 dilution of Alexa Fluor 488
goat anti-mouse IgG (A11001, Invitrogen) and Alexa Fluor
555 goat anti-rabbit IgG (A21430, Invitrogen) for 45 min
at room temperature in the dark, washed with PBS,
mounted on glass slides using the ProLong Gold Antifade
Reagent with DAPI (P36931, Invitrogen) and inspected
with a Zeiss LSM510 Meta confocal laser scanning
microscope. For detecting DNA damage, anti-gH2AX
antibody (05-636, Millipore) was used according to the
above method except that TBS (50 mM Tris–HCl (pH7.4),
150 mM NaCl) instead of PBS was used.
Statistical analysis
Statistical analyses were performed in GraphPad Prism 5.0
(GraphPad Software, San Diego, CA, USA). Statistical
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significance was determined by pairwise comparisons
using a two-tailed unpaired Student’s t-test with
a P!0.05 being considered significant. All data are
presented as meansGS.E.M.
Results
Case history
The proband is a 26 year-old woman from Italy born at full
term to healthy parents who were first cousins. Her birth
weight was 2.08 kg (K3.1 SDS). The placenta was small
and calcified, and surgical repair of a patent ductus
arteriosus was performed at 5 months. Linear growth was
reported to be retarded throughout development.
Menarche occurred precociously at 8.5 years old, and
acanthosis nigricans was first noted by the proband’s
mother at around the same age. At 12.7 years, oral glucose
tolerance testing revealed fasting hyperinsulinaemia, with
plasma insulin rising to over 5000 pmol/l after a glucose
challenge. Fasting glucose and glucose tolerance were
normal (Table 1).
Radiological investigation at 11.5 years showed
evidence of skeletal dysplasia, with widespread narrowing
of themedullary canals of the long bones. The acetabulum
appeared dysplastic with a short, thick femoral neck.
Middle and distal phalanges were shortened, and bone age
was 14.5 years. There was reduced lumbar lordosis, and
vertebral bodies had a ‘dog-like’ appearance. There was
modestly reduced interpeduncular distance at the base of
the lumbar spine, and some lumbosacral transitional
vertebrae were present. Chest and skull radiographs were
normal.
On examination at 21 years, height was 1.39 m (K4.1
SDS), with relative macrocephaly (head circumferenceC2
SDS). There were no neurodevelopmental abnormalities.
Facial dysmorphism included micrognathia, a prominent
nose, posteriorly rotated low set ears, and brachydactyly
with widespread flexural acanthosis nigricans extending
to the nasolabial crease, perioral and periocular regions.
There was moderate facial hirsutism. No nail hypoplasia
nor alopecia was found (Fig. 1). BMI was 24.5 kg/m2, with
a mildly centripetal pattern of adiposity. Oral glucose
tolerance testing revealed sustained fasting and post-
prandial severe hyperinsulinaemia, again with normal
fasting glucose and impaired glucose tolerance (Table 1).
There was severe hypertriglyceridaemia and a low HDL
cholesterol, plasma leptin was elevated and adiponectin
severely suppressed, and total testosterone was elevated
despite a low serum SHBG. Despite these severe biochemi-
cal features of insulin resistance, most commonly seen in
the face of morbid obesity, the total body fat content,
assessed using dual energy X-ray absorptiometry, was
normal. Nevertheless MRS revealed grossly elevated
hepatic triglyceride content relative to water (Table 2).
Metformin was commenced and titrated to 1.5 g/day in
divided doses.
At 26 years, oral glucose tolerance testing confirmed
persisting extreme insulin resistance (Table 1), still with
normal glucose tolerance, while treated with 1.5 g/day of
metformin. Severe dyslipidaemia also persisted, with
serum triglycerides of 25.0 mmol/l, and HDL cholesterol
0.57 mmol/l. Mildly elevated serum ALT, AST and gGT
were consistent once again with significant fatty liver.
The proband’s unaffected younger sister had a height
of 1.63 cm at 18 years (K0.09 SDS). Both parents were of
normal stature. There was no evidence of short stature nor
severe insulin resistance within the extended family.
However, the proband’s father and both grandmothers,
of lean build, were reportedly diagnosed with type 2
diabetes mellitus in their sixth decade. The proband’s
father had a normal HbA1c on therapy with metformin
Table 1 Results of serial oral glucose tolerance testing of the proband
Time (min)
12.7 years (no treatment) 21.3 years (no treatment) 26.4 years (metformin 1.5 g/day)
Glucose (mmol/l) Insulin (pmol/l) Glucose (mmol/l) Insulin (pmol/l) Glucose (mmol/l) Insulin (pmol/l)
K30 – – 5.4 201 – –
0 4.2 532 5.1 1675 5.0 219
10 – – 5.2 1661 – –
30 6.2 4375 9.4 5596 7.5 1416
60 6.2 4494 10.2 10 290 7.1 1978
90 5.3 5005 11.3 12 060 8.6 3095
120 4.6 3514 9.1 9985 6.9 5108
150 – – 8.3 10 300 – –
180 – – 7.3 8089 – –
Fasting reference range !5.6 !60 !5.6 !60 !5.6 !60
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only, while oral glucose tolerance testing in the proband’s
mother and sister revealed normal levels of both glucose
and insulin at baseline and after 120 min.
Genetic analysis
Given parental consanguinity, it was hypothesised that
the syndrome was caused by a homozygous loss-
of-function mutation not shared by the proband’s
unaffected sister. To address this, exome-wide sequencing
of the proband and her sister was performed. The resulting
list of homozygous variants was filtered to exclude those
unlikely to alter protein function, also homozygous in
the sister, or common in control populations. Seven
such variants were thus identified and validated by
Sanger sequencing (Supplementary Table 1, see section
on supplementary data given at the end of this article),
among which was a novel single nucleotide deletion
(c.1048delC) in POC1A (NM_001161580) that was absent
from all control populations and was predicted to cause
a frameshift and premature truncation of the protein
product (p.Q250Rfs*4) (Fig. 2A). Both parents and sister
were heterozygous for this deletion.
POC1A is a centrosomal protein that localises to
both the inner luminal walls and proximal ends of
centrioles (Brito et al. 2012) and plays a role in centriole
formation and maintenance (Venoux et al. 2013). It
harbours seven N terminal WD40 domains in series,
commonly involved in the assembly of multi-protein
complexes, followed by a spacer region and C terminal
coiled coil domain that is removed by the frameshift
mutation we identified (Fig. 2A).
Although we hypothesised a recessive disorder given
parental consanguinity, as an additional screen for
alternative causes of insulin resistance we also examined
variants in other genes previously shown to produce
severe insulin resistance (INSR, PIK3R1, AKT2, TBC1D4,
LMNA, PPARG, BSCL2, AGPAT2, PTRF, CAV1, PCNT,
NSMCE2, ALMS1, WRN, and BLM). After removing any
variants found in the listed genes with a non-reference
allele frequency O1% in any of the control populations,
or unlikely to have a functional impact (as determined
previously), only two variants remained (ALMS1
p.Ile3144Val and AGPAT2 p.Arg159Cys). Both of these
heterozygous variants were also seen in at least two of the
control populations (albeit with a non-reference allele
frequency below 1%) and are extremely unlikely to be
causal on their own given the very well-established
recessive mode of inheritance for both the associated
disorders. As three recent studies associated different
homozygous mutations in POC1A with primordial dwarf-
ism and facial dysmorphism highly similar to that of the
proband in this case (Sarig et al. 2012, Shaheen et al. 2012,
Koparir et al. 2015), this rare frameshift variant was
deemed to be the cause of the syndrome we describe.
Primary cell studies
Primary dermal fibroblast cultures were established
from the proband and grew well. No deficit in
A B
Figure 1
Clinical appearance of proband. (A and B) Facial appearance of the
proband showing facial dysmorphism including a triangular face with a
prominent nose, posteriorly rotated low set ears, acanthosis nigricans
extending to the nasolabial crease, perioral and periocular regions, and
facial hirsutism. No alopecia was found. Written informed consent was
given by the proband for use of clinical images.
Table 2 Growth and metabolic parameters of the proband at
21.3 years old. Ranges for leptin and adiponectin are BMI and
sex-specific
Parameter Value Reference rangea
Height (m) (SDS) 1.39 (K4.1) NA
Weight (kg) (SDS) 46.8 (C1.6) NA
BMI (kg/m2) (SDS) 24.5 (C0.8) NA
Fat (%) (SDS) 34.3 (C0.8) NA
Waist:hip 0.84 !0.85
HbA1c (mmol/mol) 31 20–38
Leptin (mg/l) 32.1 2.4–24.4
Adiponectin (mg/l) 0.9 2.6–12.6
SHBG (mmol/l) 19.7 26–110
Testosterone (nmol/l) 3.8 !2.2
Triglycerides (mmol/l) 5.0 !1.7
HDL-cholesterol (mmol/l) 0.69 O1.1
ALT (U/l) 102 0–50
gGT (U/l) 51 0–31
Liver fat (%)b 108 !8
SHBG, sex hormone-binding globulin; ALT, alanine aminotransferase;
gGT, g-glutamyl transpeptidase.
aFasting where appropriate.
bThe size of the magnetic resonance spectroscopy signal for triglyceride
protons expressed as % of the water proto signal.
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insulin-stimulated AKT phosphorylation was observed,
consistent with a lack of any defect in proximal insulin
signalling (Supplementary Figure 1, see section on
supplementary data given at the end of this article).
However, western blotting failed to detect expression of
either full length WT or truncated POC1A (Fig. 2B). Two
shorter isoforms of POC1A have been predicted, one
lacking the N-terminal 38 amino acids due to alternative
start codon usage, and the other lacking 48 amino acids
due to alternative splicing of exon 10. Exon 10 encodes a
large part of the spacer region and a small part of the coiled
coil domain of the longest isoform of POC1A (407 amino
acids long) (Fig. 2C), and is the site of the mutation
identified in this study. PCR amplification of cDNA using
primers flanking exon 10 produced two products of the
sizes expected for exon 10C and exon 10K transcripts
(Fig. 2D), suggesting that aWT exon 10K isoformmay still
be produced. Indeed, in two healthy control cell lines the
predominant PCR product was from the exon 10C
isoform whereas in the patient cells the predominant
PCR product was from the exon 10K isoform (Fig. 2D).
The antibody used in immunoblotting studies was raised
against a region of which a third is encoded by exon 10,
and so it is plausible that this putative shorter protein is
indeed expressed, but not detected in the proband’s cells.
As mutations in POC1A have been associated with
centrosome amplification (Sarig et al. 2012, Shaheen et al.
2012, Koparir et al. 2015), we next examined centrosome
number in the proband’s fibroblasts using immunostain-
ing with antibody against ALMS1, a protein localized to
the proximal ends of centrioles (Knorz et al. 2010). About
12% of interphase cells showed centrosomal amplification
with centrosome number ranging from 3 to 10 per cell.
During the mitotic phase, around 39% of cells showed
multipolar spindle formation (Fig. 3A and Supplementary
Figure 2, see section on supplementary data given at the
end of this article). In both cases, proband cells showed
over tenfold increase in the frequency of centrosomal
amplification andmultipolar spindle formation compared
to the control cells.
Despite evidence of centrosome amplification, the
proliferation rate of the proband’s cells, measured by
BrdU incorporation, did not show any difference
compared to the control cells (Supplementary Figure 3,
1 2 3
420 bp (Exon 10+)
276 bp (Exon 10–)
1: Healthy control 1
2: Healthy control 2
3: Proband
bp
400
300
200
100
500
600
700
800
900
1000
WD40 CC
407357298151 aa
POC1A
c.1048delC/p.Q350Rfs*4A
Proband Control
POC1A
Calnexin
B
Control
Proband
C
D
p. R81* (Shaheen et al. 2012) p. T120A (Koparir et al. 2015)
c.1048delC/p.Q350Rfs*4
p. L171P (Sarig et al. 2012)
Q P Q E P V
Q P R S P
*
CA G C C C C A G G A G C C C G T G A
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Figure 2
POC1A frameshift mutation and detection of its protein and mRNA
expression. (A) Schematic of POC1A showing that the protein contains a
WD40-repeat domain and a coiled coil (CC) domain separated by a spacer
region. The mutation site is indicated by the arrow and the deletion
mutation and resulting frameshift are shown in a sequence chromatogram.
(B) Western blot analysis of primary dermal fibroblast lysates of the
proband and of a healthy control. (C) Three splicing variants of POC1A
were aligned and mutation in the proband in this study as well as
mutations described in three previous reports were indicated in red letters.
Amino acids encoded by 11 exons were indicated in black and blue letters.
Numbers of amino acids and the predicted molecular sizes of each isoforms
were indicated at the end of each isoform sequence. Locations of primers
used for PCR to reveal the expected alternative splicing of exon 10 were
indicated by red arrows (the reverse primer was in the 3
0
UTR). (D) PCR
products using primers as indicated in (C) were revealed by an agarose gel
(1%) with SYBR Safe in the gel to stain amplified DNAs.
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see section on supplementary data given at the end of
this article). Although centrosome amplification can lead
to multipolar spindle formation, we found that primary
cilia in proband dermal fibroblasts were of normal length
and frequency (Supplementary Figure 4), with multiple
centrosomes always clustered at the basal body of a single
cilium (Fig. 3B).
Supernumerary centrioles/centrosomes may arise due
to overduplication, aberrant de novo synthesis, mitotic
skipping, cleavage failure or cell fusion (Anderhub et al.
2012). DNA content analysis by FACS revealed a cell cycle
distribution profile for the proband’s dermal fibroblasts
that was indistinguishable from healthy control cells
(Supplementary Figure 5A), suggesting that centrosome
amplification in the proband’s cells was due to over-
duplication rather than cleavage failure, mitotic skipping
or cell fusion, as these would produce cells with 8N DNA
content. In line with this, karyotype analysis in the
proband fibroblasts was normal (Supplementary
Figure 5B).
As for primary cilia, where centrosome clustering was
seen in the region of the basal body (Fig. 3B), clusters of
centrosomes were also seen at many mitotic spindles
(Fig. 4A). Centrosome clustering prevents multipolar cell
division, however, it can lead to syntelic or merotelic
kinetochore attachments which can lead in turn to
chromosome mis-segregation (Anderhub et al. 2012,
Vitre & Cleveland 2012). One consequence of chromo-
some mis-segregation, if not corrected by the activity of
Aurora-B, is the formation of anaphase bridges or lagging
chromosomes, detectable as micronuclei (Anderhub et al.
2012, Vitre & Cleveland 2012). These abnormalities were
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Figure 3
POC1A frameshift mutation and associated centrosome and basal body
amplification. (A) Immunofluorescence analysis of dermal fibroblasts
shows normal centrosome duplication and bipolar spindle formation in
healthy control cells and centrosome amplification and multipolar spindle
formation in proband cells. Centrosomes (red) were revealed using
anti-ALMS1 antibodies and spindle fibres (green) were revealed using
anti-acetylated tubulin antibodies together with appropriate Alexa Fluor
conjugated secondary antibodies. Nuclei (blue) were revealed with DAPI.
Bar charts show percentages of cells with centrosome amplification in
interphase and mitotic phase. Error bars represent the S.E.M. Asterisks
indicate statistical significance (*P!0.05, ***P!0.001) as analysed by the
Student’s t-test. (B) Example of amplification of the basal body (red, stained
with anti-ALMS1 antibodies) of a primary cilium (green, stained with
anti-acetylated tubulin) in the proband’s dermal fibroblasts compared to
the normal appearance of a healthy control.
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observed at a higher level in the proband cells with
centrosome amplification (Fig. 4B) with micronuclei
staining avidly for anti-gH2AX, suggesting the presence
of double stranded DNA breaks (Fig. 4C). This was
consistent with Western blotting which showed gH2AX
to be higher in proband cells than in those from two
healthy control individuals (Supplementary Figure 6,
see section on supplementary data given at the end of
this article).
Discussion
We used exome-wide sequencing to investigate a single
proband with consanguineous parents and a rare
syndrome of primordial dwarfism, facial dysmorphism,
skeletal dysplasia, and extreme, dyslipidaemic insulin
resistance. We identified seven rare, functional homo-
zygous variants, among which was a frameshift
mutation in POC1A, which was associated during the
course of our study by three groups with a similar
syndrome in five consanguineous families from the
Middle East (Sarig et al. 2012, Shaheen et al. 2012, Koparir
et al. 2015). Three of these families harboured one of two
missense mutations (Sarig et al. 2012, Koparir et al. 2015),
while the other three families had in common an early
nonsense mutation, although cellular studies suggested
significant translational readthrough of the mutation
(Shaheen et al. 2012).
DAPI/γH2AX/ALMS1 DAPI/γH2AX/ALMS1
A
C
B
Figure 4
Centrosome clustering and evidence of DNA damage in cells harbouring
centrosome amplification. (A) Centrosome clustering in proband dermal
fibroblasts, with either even (left) or uneven partitioning between spindle
poles (right). Immunostaining was performed using antibodies as in Fig. 3.
(B) Example of an anaphase bridge and resulting micronuclei formation in
proband cells. (C) DNA damage foci in the nuclei and micronuclei of
proband dermal fibroblasts with centrosome amplification revealed by
immunofluorescence staining using anti-gH2AX antibody.
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On the basis of the close similarity among the reported
phenotypes, it is highly likely that the new POC1A variant
is the cause of the syndrome we describe. The growth
parameters, facial dysmorphism and skeletal features of
the proband in this report are highly similar to other
published cases (Koparir et al. 2015), and although the
large majority of patients reported to date are of
prepubertal age, one other patient has been described
with precocious puberty (Koparir et al. 2015), which may
play a role in the short final height of the proband we
describe. There are significant phenotypic differences
among patients reported to date. Most prominently, the
proband we describe had no ectodermal dysplasia,
reported in three of four families to date (Shaheen et al.
2012, Koparir et al. 2015), and, conversely, did have
extreme, dyslipidaemic insulin resistance, which was not
clearly described in other reports. Differing genetic back-
grounds may contribute to these differences, as suggested
by the occurrence of type 2 diabetes of onset in middle age
in several members of the family we describe, albeit
without the extreme insulin resistance of the proband. We
could not attribute this to rare variants in other genes
previously associated with Mendelian insulin resistance,
and nor were there any obvious functional interactions
between POC1A and other genes harbouring rare homo-
zygous variants in this study. Nevertheless such inter-
actions cannot be formally excluded in an individual
patient, and nor can an effect of heterozygous POC1A loss
of function on susceptibility to type 2 diabetes be ruled out
based on the data we present.
Some of the phenotypic differences may alternatively
be explained by the differing nature of the POC1A
mutations involved in each report: previous cases were
attributed to POC1A hypomorphism due to partial read-
through of a premature nonsense mutation in one report
(Shaheen et al. 2012), and to rare missense mutations in
two others (Sarig et al. 2012, Koparir et al. 2015). In all
cases, all protein products of the gene were predicted to be
affected. In the current report, in contrast, we identified a
frameshift mutation predicted to abolish expression of
two out of three protein isofoms. We provide evidence
that one of the predicted POC1A mRNA species, lacking
exon 10 and thus the frameshift mutation, is indeed
expressed, although formal proof of the existence of the
corresponding exon 10K isoform of POC1A protein is
lacking. The exon 10K isoform retains theWD40 domain,
required for targeting POC1A to centrioles but lacks
almost half of the coiled coil POC1 domain, implicated
in interactions with other proteins (Keller et al. 2009). It is
therefore conceivable that WT exon 10K POC1A protein,
if expressed, can partially compensate for the loss of the
exon 10C isoforms in our patient. Examination of further
cases will be required to build a more robust view of
genotype–phenotype correlation.
Despite the lack of detailed metabolic assessment
reported for other cases, two affected males in one report
were said to have developed unusually early type 2
diabetes (Shalev et al. 2012), at 20 and 24 years old, a
common feature of severe insulin resistance. Moreover, a
further patient has been identified with clearly demon-
strated severely dyslipidaemic insulin resistance (Prof
Fowzan Alkuraya, King Faisal Specialist Hospital and
Research Center, Riyadh, personal communication),
strongly suggesting that severe insulin resistance is a
significant component of the syndrome associated with
genetic defects in POC1A. It is notable that the majority of
patients described to date are of prepubertal age (Koparir
et al. 2015), when even many highly penetrant forms of
Mendelian severe insulin resistance are yet to be clinically
expressed, and we suggest that metabolic evaluation for
severe insulin resistance is warranted for patients with this
syndrome from puberty onwards.
The insulin resistance subphenotype we report,
including severe dyslipidaemia, suppressed adiponectin
and severe fatty liver is closely similar to that shared by
lipodystrophy (Semple et al. 2011) and severe obesity, and
also, interestingly, by both Alstro¨m syndrome (Collin et al.
2002, Hearn et al. 2002) and MOPDII (Rauch et al. 2008,
Willems et al. 2010), each accounted for by defects in large
centriolar or pericentriolar proteins. Alstro¨m syndrome is
widely regarded as a ciliopathy (Girard & Petrovsky 2011),
while in MOPDII the core cellular defect appears to be
inefficient mitosis (Klingseisen & Jackson 2011, Rauch
2011). A wide number of other primary ciliopathies,
notably the Bardet Biedl syndrome group, are known,
but it is not clear that they feature insulin resistance that is
out of proportion to the degree of obesity, while most
forms of primordial dwarfism have also not been
associated with severe insulin resistance. It thus appears
that only a subset of genetic defects affecting the
centrosome give rise to extreme, dyslipidaemic insulin
resistance. Further investigation of the pathogenesis of
these unusual metabolic phenocopies of the prevalent
metabolic syndrome is likely to yield novel information
relevant to common disease as well as to these rare
Mendelian disorders.
The primary cell phenotype we describe is in key
respects consistent with previous studies, including
centrosomal amplification and multipolar spindle for-
mation, which we suggest is accounted for by primary
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centrosome overduplication. The threefold greater level of
cells with supernumerary centrosomes seen duringmitotis
rather than during interphase is likely to be a consequence
of prolonged mitosis due to kinetochore mis-attachment
and chromosome mis-segregation (Silkworth et al. 2009).
Although themechanisms bywhich cells keep centrosome
numbers constant during cell division remain to be fully
elucidated it is generally believed that two distinct ‘rules’
apply. The first stipulates that centrosomes duplicate once
only per cell cycle and the second that only one daughter
centriole is produced per parent centriole (Nigg 2007).
Although many centrosomal proteins have been ident-
ified, major centriole duplication factors are limited, with
SAS6 and Plk4 being the best characterised (Kleylein-Sohn
et al. 2007, Strnad et al. 2007, Holland et al. 2010). Over-
expression of SAS6 and Plk4 causes near-simultaneous
formation of multiple daughter centrioles (Kleylein-Sohn
et al. 2007, Strnad et al. 2007), and Plk4 kinase activity
normally limits centrosome overduplication by auto-
regulating its own stability (Holland et al. 2010, 2012).
Investigating whether POC1A interacts functionally with
these factors is an obvious route for further study.
Although we confirm multipolar spindle formation,
multi-cilia formation was not observed. This is consistent
with previous knockdown studies which showed that the
paralogue POC1B, but not POC1A, is required for
ciliogenesis in human cells (Pearson et al. 2009). Similarly,
Venoux et al. (2013) recently observed that although
POC1A and POC1B act together in human cells to ensure
centriole integrity, only POC1B had additional, non-
redundant functions in cell. On the other hand, ciliary
formation was reported to be severely suppressed in
primary skin cells from one previous patient studied,
although sonic hedgehog (SHH) signalling in POC1A-
knockdown cells was unaffected (Shaheen et al. 2012).
Whether this discrepancy has a methodological basis,
or whether it relates to the different molecular defects
present in POC1A in these different studies, remains
unclear.
Multiple centrosomes were always clustered at the
basal body of a single cilium in our patient cells. Such
centrosome clustering is believed to be a survival
mechanism, permitting cells to avoid multipolar division
(Ganem et al. 2009, Vitre & Cleveland 2012) by under-
going pseudo-bipolar mitosis (Anderhub et al. 2012, Vitre
& Cleveland 2012). Chromosomemis-segregation can also
lead to aneuploidy and although karyotypic analysis failed
to detect this in the proband cells, it remains possible that
low levels of aneuploidy in vivo resulting from chromo-
some mis-segregation could play some role in causing
cellular malfunction in our patient, for example via
proteotoxic and energetic stress which can cause cell
cycle arrest or apoptosis (Pfau & Amon 2012).
In summary, we describe a novel frameshift mutation
in POC1A in association with short stature, skeletal
dysplasia and extreme, dyslipidaemic insulin resistance.
The truncating mutation abolished expression of the
mutation-bearing exon10C isoform in patient, although
the WT exon 10K isoform may still be expressed and
thereby partially compensate for abolished expression of
exon 10C isoforms. Primary dermal fibroblasts exhibited
centrosome amplification with evidence of increased DNA
damage, but no readily detectable aneuploidy.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
JME-15-0090.
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